Gabapentin Capsule
Product Images NDC 70518-0293

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-0293). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 300mg 70518 0293 00

Gabapentin 300 mg oral capsules in a repackaged bottle by RemedyRepack Inc. The label notes a quantity of 90 capsules and indicates the manufacturer as Ascend Labs, LLC, Montvale, NJ. It includes instructions to see the package insert for directions, storage conditions, and standard warnings.*

FDA Label Image

Mm2 (Gabapentin 300mg 70518 0293 01)

Gabapentin 300 mg oral capsules packaging label from RemedyRepack Inc. The label indicates a quantity of 270 capsules, with manufacturer information for Ascend Labs, LLC, Montvale, NJ. It includes a barcode and a QR code, and mentions directions for use and storage instructions between 20-25°C with permitted excursions. The label advises keeping the medication out of reach of children.*

FDA Label Image

Mm3 (Gabapentin 300mg 70518 0293 02)

Gabapentin 300 mg oral capsules packaging label by RemedyRepack Inc. The label states quantity of 120 capsules, with NDC number 70518-0293-02 and manufacturer Ascend Labs, LLC, Montvale, NJ. It includes storage instructions and a barcode with a QR code on a white background with purple accents.*

FDA Label Image

Mm4 (Gabapentin 300mg 70518 0293 03)

Label for Gabapentin 300 mg capsules by RemedyRepack Inc. The label indicates a quantity of 28 capsules and includes manufacturer information for Ascend Labs, LLC, Montvale, NJ. Storage instructions are provided along with a barcode and a QR code. The label specifies this is a prescription drug with the NDC 70518-0293-03.*

FDA Label Image

Mm5 (Gabapentin 300mg 70518 0293 04)

Gabapentin 300 mg capsule label showing a quantity of 180 capsules. The label includes the brand name Remedy Repack with a purple and white color scheme. It specifies the product as Rx only with NDC 70518-0293-04, manufactured by Ascend Labs, LLC, Montvale, NJ. Storage instructions are provided, along with a QR code and barcode on the label.*

FDA Label Image

Mm6 (Gabapentin 300mg 70518 0293 05)

Gabapentin 300 mg oral capsules label by RemedyRepack Inc. The label indicates a quantity of 60 capsules and includes manufacturer information: Ascend Labs, LLC, Montvale, NJ. It features an NDC barcode, a QR code, and usage/storage directions referencing a package insert for further details.*

FDA Label Image

Mm7 (Gabapentin 300mg 70518 0293 06)

Gabapentin 300 mg capsule label from RemedyRepack Inc. It specifies a quantity of 30 capsules and includes details such as the NDC number 70518-0293-06, manufacturer Ascend Labs, LLC, Montvale, NJ, and storage instructions. The label features the RemedyRepack logo and a barcode along with a QR code.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A mathematical formula illustrating the creatinine clearance (CLCr) calculation based on age, weight, serum creatinine, and an adjustment factor for female patients. The formula calculates CLCr as (140 minus age in years) multiplied by weight in kilograms, divided by 72 times serum creatinine in mg/dL, with a multiplication factor of 0.85 for females.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain score over 8 weeks comparing Gabapentin 3600 mg/day (solid triangles) and placebo (open circles). The x-axis represents weeks from baseline to week 8, and the y-axis shows mean pain scores ranging from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph displaying mean pain scores over a 7-week period. The x-axis represents weeks from baseline to week 7, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Three groups are shown: Placebo (open circles), Gabapentin 1800 mg/day (solid triangles), and Gabapentin 2400 mg/day (open triangles), with pain scores decreasing over time for gabapentin groups compared to placebo.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. Study 1 compares placebo (PBO) at 12% to Gabapentin (GBP) 3600 mg at 29%. Study 2 shows placebo at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance indicators for p-values are also shown.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart showing the percentage difference versus daily dose in mg for Gabapentin. It compares data points from three different studies labeled as study a, study b, and study c, with daily doses ranging from 600 mg to 1800 mg. Differences appear to increase with dose and vary across studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.